

2 July 2014

## Board appointment

- **Kris Knauer appointed to the board as an Executive Director**
- **Role is to assist in the fast tracking of the HRV Technology**
- **Highly experienced in strategy and corporate matters**
- **Peter May resigns from the board**

---

**Sydney, Australia July 2014:** BioProspect ("BPO") is pleased to announce the appointment of Kris Knauer as an Executive Director.

Kris has a wealth of experience particularly in ASX Listed companies and is also a key shareholder and convertible noteholder of the Company. Kris has been a consultant to the Company and has been actively involved in the due diligence process and subsequently in providing corporate and strategic advice to BioProspect. Kris will focus corporate matters such as the Board and Senior Management composition and structure, Capital structure, and the ongoing funding requirements for commercialisation of Invatec's HRV technology for the diagnosis of Depression and other Mental Health conditions.

Kris has a Bachelor of Science (Honours). Mr Knauer also has over 15 years experience in finance and corporate advisory services. He is currently Executive Director Equities at Novus Capital Limited with a key focus on smaller listed companies. Mr Knauer is currently the Executive Chairman of Esperance Minerals Limited (ASX: ESM), Non-Executive Chairman of Astro Resources NL (ASX: ARO), Non-Executive Director of Greenvale Mining NL (ASX: GRV) and a former director of Citadel Resource Group Limited (ASX: CGG).

A monthly fee of \$4,000 will be paid to Mr Knauer for the provision of his services to the Company.

Peter May has resigned from the board effective from the 30 June 2014. Mr May will continue to be a consultant to BPO so as to assist in the strategic direction of the technology that relates to the human health and personal care, animal health and nutrition and agricultural sectors. The board thanks Mr May for his valuable contribution, particularly during the period of the acquisition of the HRV technology.

<b>Further Information:</b>	
Mr Vince Fayad Non-Executive Chairman E: <a href="mailto:vfayad@pkflawler.com.au">vfayad@pkflawler.com.au</a> T: +61 (0) 414 752 804	Media Enquiries to: Matthew Mahon or Richard Amos Royce Consulting E: <a href="mailto:matthew@royce.com.au">matthew@royce.com.au</a> T: +61 (0) 413 101 860 or +61 (0) 3 8628 9300

## **About BioProspect**

BioProspect (ASX: BPO) is a medical technology company developing a new paradigm in psychiatric diagnosis. The Company's Heart Rate Variability (HRV) technology is based on the scientific finding that human heart rates, including certain tell tale changes, are sensitive measures for depression. The HRV technology consists of a heart monitor that sends recordings wirelessly to the internet where a proprietary algorithm analyses and delivers a report back to the clinician. The HRV technology is the first objective, evidence-based approach to the diagnosis of depression and other affective disorders. The technology has already benefited from 10 years of research and BioProspect is currently undertaking a number of pivotal trials to further validate its clinical utility.

The company is also engaged in developing and commercialising other technology in the human health and personal care, animal health and nutrition and agricultural sectors. This includes **AGRIPRO**<sup>®</sup> animal health and nutrition products, **Qcide**<sup>®</sup> a new, environmentally friendly treatment for household and agricultural pests, **TERMILONE**<sup>®</sup> which is the registered Trade Mark for the natural Eremophilone Oil, and **REGEN**<sup>®</sup> human health products. The Company also has an investment in Frontier Oil Corporation Limited an unlisted public company based in the Philippines. Located in Sydney, BioProspect is listed on the Australian Stock Exchange.